- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04567589
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
21. oktober 2020 opdateret af: Allergan
A Cross-sectional Study Among Healthcare Professionals in Canada to Assess Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures
This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Healthcare Professionals (HCPs).
Studieoversigt
Status
Trukket tilbage
Betingelser
Detaljeret beskrivelse
Data will be collected via web-based data capture by HCPs submitting surveys.
The survey will be conducted in a single wave over 6 months.
All data will be maintained in compliance with local regulations.
Undersøgelsestype
Observationel
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92622
- Clinical Trials Registry Team
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
N/A
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
The survey will endeavor to collect 150 completed HCP surveys.
Beskrivelse
Inclusion Criteria:
- HCPs have prescribed Fibristal for the indication of uterine fibroids within the past 6 months.
- HCPs have provided permission to share their responses in aggregate to Health Canada.
Exclusion Criteria:
- HCPs who participated in the cognitive pre-testing of the survey questionnaire to be used for the study.
- HCPs who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past 5 years.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of HCPs with correct responses to the knowledge level questions.
Tidsramme: 18 - 24 months
|
Correct responses to knowledge-related questions based on the contents of the Fibristal aRMMs.
|
18 - 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of HCPs that recall receiving and reading the HCP Letter and HCP Brochure .
Tidsramme: 18 - 24 months
|
HCP's recall of receiving and reading the HCP Letter and HCP Brochure .
|
18 - 24 months
|
Percenatage of HCPs that recall distributing the Fibristal Patient Alert Card
Tidsramme: 18 - 24 months
|
HCP's recall of distributing the Fibristal Patient Alert Card
|
18 - 24 months
|
Percentage of patients who recall counselling patients on information included in the Patient Alert Card
Tidsramme: 18 - 24 months
|
HCP's recall of counselling patients on information included in the Patient Alert Card
|
18 - 24 months
|
Overall score for each HCP will be calculated that totals the correct responses to all of the knowledge-related questions
Tidsramme: 18 - 24 months
|
Composite score on the level of HCPs knowledge across all knowledge-related questions.
|
18 - 24 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Ahunna Ukah, Allergan
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
30. september 2020
Primær færdiggørelse (Forventet)
28. februar 2021
Studieafslutning (Forventet)
28. februar 2021
Datoer for studieregistrering
Først indsendt
1. september 2020
Først indsendt, der opfyldte QC-kriterier
23. september 2020
Først opslået (Faktiske)
28. september 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
22. oktober 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. oktober 2020
Sidst verificeret
1. oktober 2020
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CMO-EPI-WH-0618
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.
To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.
More information can be found on http://www.allerganclinicaltrials.com/.
IPD-delingstidsramme
After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.
IPD-delingsadgangskriterier
To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Uterine fibromer
-
Northwestern UniversityAfsluttetEndometriose | Uterin fibroid | Uterin adenomyose | Endometriecyste | Fibroid livmoder | Uterus myom | Uterin cysteForenede Stater
-
West China Second University HospitalAktiv, ikke rekrutterendeUterin sarkom | Uterin fibroid | Uterin leiomyosarkomKina
-
Next Biomedical Co., Ltd.AfsluttetUterin fibroid | Uterin myomKorea, Republikken
-
Kangbuk Samsung HospitalUkendtUterin fibroidKorea, Republikken
-
Ain Shams Maternity HospitalAfsluttet
-
Unity Health TorontoAfsluttet
-
Mansoura UniversityAfsluttetKejsersnit | Uterin fibroid
-
University Magna GraeciaUkendt
-
Merit Medical Systems, Inc.Ikke rekrutterer endnuUterin fibroid